Artificial intelligence (AI) has been implemented in multiple fields of medicine to assist in the diagnosis and treatment of patients. AI implementation in radiology, more specifically for breast imaging, has advanced considerably. Breast cancer is one of the most important causes of cancer mortality among women, and there has been increased attention towards creating more efficacious methods for breast cancer detection utilizing AI to improve radiologist accuracy and efficiency to meet the increasing demand of our patients. AI can be applied to imaging studies to improve image quality, increase interpretation accuracy, and improve time efficiency and cost efficiency. AI applied to mammography, ultrasound, and MRI allows for improved cancer detection and diagnosis while decreasing intra- and interobserver variability. The synergistic effect between a radiologist and AI has the potential to improve patient care in underserved populations with the intention of providing quality and equitable care for all. Additionally, AI has allowed for improved risk stratification. Further, AI application can have treatment implications as well by identifying upstage risk of ductal carcinoma in situ (DCIS) to invasive carcinoma and by better predicting individualized patient response to neoadjuvant chemotherapy. AI has potential for advancement in pre-operative 3-dimensional models of the breast as well as improved viability of reconstructive grafts.
8 May 2019 in American Journal of Medical Genetics Part A
Background/Objective: The objective was to evaluate the standalone performance of an AI system, Transpara 1.7.1 (ScreenPoint Medical), in screening mammography cases proceeding to stereotactic biopsy using histopathological results as ground truth. Methods: This retrospective study included 202 asymptomatic female patients (mean age: 57.8 years) who underwent stereotactic biopsy at a multicenter academic institution between October 2022 and September 2023 with a preceding screening mammogram within 14 months. Transpara AI risk scores were compared to pathology results (benign versus malignant). Performance metrics for AI including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve (AUC) were calculated. Results: Transpara AI classified 20 of 39 malignant findings (51%) as elevated risk compared with 50 of 211 total findings (24%). AI score was positively correlated with malignancy (r = 0.29, p < 0.001). Sensitivity for detecting malignancy (classifying as intermediate or elevated risk) was 94.9% (95% CI: 81.4–94.1), specificity was 24.4% (95% CI: 18.3–31.7), PPV was 22.2% (95% CI: 16.3–29.4), and NPV was 95.5% (95% CI: 83.3–99.2). Transpara had fair performance in detecting breast cancer with AUC 0.73 (95% CI: 0.63–0.82). Conclusions: Transpara AI is a useful screening mammography triage tool. Given its high sensitivity and high negative predictive value, AI may be used to guide radiologists in making biopsy or follow up recommendations. However, the high false-positive rate and presence of two false negatives underscore the need for radiologists to use caution and clinical expertise when interpreting AI results.
Short-course glucocorticosteroids are being used and tocilizumab (TCZ) had been used to treat patients with severe coronavirus disease 2019 (COVID-19) disease. These agents, when administered individually, have been associated with tuberculosis (TB) during chronic use. We report a case of TB in a 44-year-old male with diabetes and severe COVID-19 who received high-dose short-course glucocorticosteroids and a single dose of TCZ. The clinical presentation was atypical with unresolving fevers and leukocytosis, progressive lower lobe cavities, and hilar adenopathy. Delayed diagnosis led to prolonged hospitalization and extensive antibiotic use.
9 June 2021 in Journal of Scientific Innovation in Medicine